Quantcast

Latest tumor Stories

2014-05-30 08:24:56

- Results from Phase I study of investigational oncology compound ABT-414 in patients with recurrent or unresectable glioblastoma multiforme, an aggressive type of brain cancer NORTH CHICAGO, Ill., May 30, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one...

2014-05-20 23:08:25

Barnes-Jewish Hospital was one of the first hospitals in the country to offer patients the opportunity to have brain surgery using technology that reduced the need for follow-up surgery. Now, its neurosurgery team has reached a milestone by performing more than 1,000 cases using its moveable intraoperative MRI system – more than any other center in the United States. St. Louis (PRWEB) May 20, 2014 Barnes-Jewish Hospital was one of the first hospitals in the country to offer patients the...

2014-05-19 12:27:37

LONDON, May 19, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Cancer Profiling and Pathways: Technologies and Global Marketshttp://www.reportbuyer.com/pharma_healthcare/diseases/cancer/cancer_profiling_pathways.htmlSTUDY GOALS AND OBJECTIVESThis BCC Research report, BIO073B: Cancer Profiling and Pathways: Technologies and Global Markets, provides a detailed overview and thorough analysis and insight of the present and future cancer profiling and...

2014-05-19 10:21:58

University of Cincinnati Academic Health Center About one in seven men will develop prostate cancer over the course of a lifetime, and about one in 36 men will die from it. This is why findings by Cincinnati Cancer Center researchers, showing that a tumor suppressive microRNA, when activated by an anti-estrogen drug, could contribute to development of future targeted therapies, are important. These findings are published in the May 16, 2014 edition of the journal PLOS ONE....

herpes virus attack a brain tumor cell
2014-05-18 03:00:47

Harvard Stem Cell Institute (HSCI) Harvard Stem Cell Institute (HSCI) scientists at Massachusetts General Hospital have a potential solution for how to more effectively kill tumor cells using cancer-killing viruses. The investigators report that trapping virus-loaded stem cells in a gel and applying them to tumors significantly improved survival in mice with glioblastoma multiforme, the most common brain tumor in human adults and also the most difficult to treat. The work, led by Khalid...

2014-05-16 08:26:45

DUBLIN, May 16, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/6mvft5/circulating_tumor) has announced the addition of the "Circulating Tumor Cells and Cancer Stem Cells Technologies - Global Strategic Business Report" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 This report analyzes the worldwide markets for Circulating Tumor Cells and Cancer Stem Cells Technologies in US$ Million. The report provides separate...

2014-05-16 08:26:16

30mg/m2 dose cohort had been completed; enrollment of 40mg/m2 cohort has been initiated VANCOUVER, British Columbia and MENLO PARK, Calif., May 16, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") is pleased to provide an update on the company's ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma multiforme (GBM). DelMar has completed enrollment of VAL-083 dose Cohort 6 and advanced to Cohort 7. DelMar most recently presented...

2014-05-15 08:32:30

First Case Study Announced While Broader Data Being Collected; Evidence Indicates Substantial Tumor Necrosis and Initial Tumor Regression BETHESDA, Md., May 15, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided an initial patient case study, showing signs of tumor necrosis (tumor death) and initial tumor regression, from the Company's ongoing...

2014-05-15 08:31:40

Comprehensive Molecular Profiling Provides Oncologists Treating Patients with Rare, Aggressive or Refractory Cancers with Better Understanding of How to Treat Cancer IRVING, Texas, May 15, 2014 /PRNewswire/ -- Caris Life Sciences, a leading biosciences company focused on fulfilling the promise of precision medicine, today announced the acceptance of 34 key clinical studies by the American Society of Clinical Oncology (ASCO) for their 50(th) annual meeting to be held May 30 through June 3 in...

2014-05-14 16:29:06

WHIPPANY, N.J., May 14, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that data from its oncology portfolio, including NEXAVAR(®) (sorafenib) tablets, Xofigo(®) (radium Ra 223 dichloride) injection and Stivarga(®) (regorafenib) tablets, will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 - June 3, in Chicago, IL (USA). Bayer will also present data from its late stage clinical pipeline, investigating...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related